MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-19-2022
Calliditas Therapeutics AB (publ) ROA Ratio 2011-2026 | CALT
Annual ROA Ratio Calliditas Therapeutics AB (publ)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -34.9 | -28.78 | - | - | -139.34 | - | - | - | - | - | - |
All numbers in SEK currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -28.78 | -139.34 | -67.67 |
Quarterly ROA Ratio Calliditas Therapeutics AB (publ)
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -30.8 | -30.8 | -29.12 | -42.84 | -37.33 | -23.61 | -27.73 | -18.14 | -8.25 | -4.12 | -4.12 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in SEK currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -4.12 | -42.84 | -23.35 |
ROA Ratio of other stocks in the Drug manufacturers industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
-17.34 | - | - | $ 754 M |  USA |
 |
Canopy Growth Corporation
CGC
|
-65.18 | $ 1.11 | 4.25 % | $ 119 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
-71.31 | - | 7.5 % | $ 6.35 M | USA |
 |
Catalent
CTLT
|
-10.69 | - | - | $ 11.5 B | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-242.23 | - | 0.86 % | $ 117 M | USA |
 |
DURECT Corporation
DRRX
|
-61.13 | - | - | $ 50.1 M | USA |
 |
Endo International plc
ENDP
|
-47.69 | - | - | $ 28.9 M |  Irlanda |
 |
Agile Therapeutics
AGRX
|
-141.05 | - | 10.11 % | $ 58.2 M | USA |
 |
Evoke Pharma
EVOK
|
-110.24 | - | - | $ 36.6 M | USA |
 |
Alimera Sciences
ALIM
|
-13.11 | - | - | $ 142 M | USA |
 |
Evolus
EOLS
|
-22.86 | $ 5.57 | 34.75 % | $ 359 M | USA |
 |
Cronos Group
CRON
|
-3.8 | $ 2.65 | 1.92 % | $ 1.38 B | Canada |
 |
Avadel Pharmaceuticals plc
AVDL
|
-29.73 | - | - | $ 2.06 B |  France |
 |
Harrow Health
HROW
|
-1.29 | $ 40.0 | 3.61 % | $ 1.47 B | USA |
 |
Jupiter Wellness
JUPW
|
-673.3 | - | - | $ 33.6 M | USA |
 |
China Pharma Holdings
CPHI
|
-31.81 | $ 0.59 | 7.93 % | $ 10.3 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
-2.52 | $ 3.8 | -17.03 % | $ 53.4 M | USA |
 |
HEXO Corp.
HEXO
|
-8.75 | - | 2.45 % | $ 38.1 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
6.13 | - | - | $ 193 M | Canada |
 |
Aurora Cannabis
ACB
|
-26.69 | $ 3.69 | 5.89 % | $ 86.3 M | Canada |
 |
Athenex
ATNX
|
-50.69 | - | -23.39 % | $ 1.76 M | USA |
 |
Organogenesis Holdings
ORGO
|
0.17 | $ 2.93 | 1.92 % | $ 386 M | USA |
 |
Emergent BioSolutions
EBS
|
-41.71 | $ 8.95 | 0.34 % | $ 458 M | USA |
 |
ProPhase Labs
PRPH
|
21.06 | - | - | $ 5.07 M | USA |
 |
Assertio Holdings
ASRT
|
-115.89 | $ 12.19 | 2.48 % | $ 866 M | USA |
 |
Radius Health
RDUS
|
-38.66 | - | - | $ 1.42 B | USA |
 |
Rockwell Medical
RMTI
|
-16.18 | $ 0.91 | 0.93 % | $ 21.2 M | USA |
 |
Bausch Health Companies
BHC
|
-2.16 | $ 5.7 | -0.61 % | $ 2.08 B | Canada |
 |
Lannett Company
LCI
|
-47.81 | - | 1.15 % | $ 7.11 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
8.78 | - | -39.89 % | $ 27.7 M | USA |
 |
OrganiGram Holdings
OGI
|
-23.59 | $ 1.42 | 3.28 % | $ 402 M | Canada |
 |
Perrigo Company plc
PRGO
|
-16.7 | $ 11.66 | 2.42 % | $ 1.61 B | USA |
 |
Sundial Growers
SNDL
|
-16.12 | $ 1.55 | 1.48 % | $ 3.37 M | Canada |
 |
TherapeuticsMD
TXMD
|
-23.73 | $ 2.25 | 1.35 % | $ 23.5 M | USA |
 |
Pacira BioSciences
PCRX
|
-6.41 | $ 22.97 | 3.94 % | $ 1.06 B | USA |
 |
Veru
VERU
|
-62.57 | $ 2.54 | 0.8 % | $ 343 M | USA |
 |
PetIQ
PETQ
|
0.25 | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
-32.94 | - | - | $ 1.08 B | USA |
 |
Viatris
VTRS
|
4.16 | $ 14.88 | -0.1 % | $ 17.9 B | USA |
 |
PLx Pharma
PLXP
|
-60.18 | - | -27.8 % | $ 2.56 M | USA |
 |
Recro Pharma
REPH
|
-8.65 | - | -4.76 % | $ 65.3 M | USA |
 |
cbdMD
YCBD
|
-1.44 | $ 0.74 | -4.01 % | $ 3.19 M | USA |
 |
Relmada Therapeutics
RLMD
|
-101.27 | $ 4.77 | 2.14 % | $ 144 M | USA |
 |
SCYNEXIS
SCYX
|
52.21 | $ 0.76 | 1.21 % | $ 36.4 M | USA |
 |
Solid Biosciences
SLDB
|
-66.1 | $ 6.18 | 3.69 % | $ 252 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-25.25 | $ 2.74 | -0.36 % | $ 3.4 M | USA |
 |
Tricida
TCDA
|
-104.78 | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
-33.73 | $ 7.42 | 0.82 % | $ 4.59 B | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
-63.1 | - | - | $ 55.5 M | USA |